ModifiedUnitedHealthcarePolicy CS054.W

High-frequency chest wall oscillation (HFCWO) airway clearance devices — Medical necessity and coverage

This policy governs medical necessity and coverage of airway clearance devices — primarily high-frequency chest wall oscillation systems — for UnitedHealthcare members, specifying indications, rental trial requirements, and excluded uses. It applies nationally except where state-specific policies are listed.

Policy Summary

PayerUnitedHealthcare

PolicyHigh-frequency chest wall oscillation (HFCWO) airway clearance devices — Medical necessity and coverage

Policy CodePolicy CS054.W

Change TypeCoverage criteria clarifieddocumentation requirements added

Effective DateMar 1, 2026

Next Review Date

Key ActionDocument an initial 2-month rental trial demonstrating tolerance and efficacy and submit required medical records for prior authorization.

SourceLink

POLICY UPDATE CHANGES

Updated medical necessity clinical coverage criteria language for high-frequency chest wall oscillation (HFCWO) systems.

Added specific medical records documentation items used for reviews, including device requested, trial status, imaging/results, comorbidities, and demonstration of proper use for continuation beyond a two-month trial.

Replaced reference to InterQual® Client Defined, CP: Durable Medical Equipment, Secretion Clearance Devices (Custom) - UHG with InterQual® Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG.

Replaced 'failed standard treatments to adequately mobilize retained secretions' with wording requiring documentation of treatments tried, failed, or contraindicated, including dates, duration, and reason for discontinuation.

2-monthrequired initial rental trial duration for HFCWO

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Unprovenother uses considered

03/01/2026policy sections updated on

Coverage Criteria for HFCWO and Related Devices

Medically Necessary Indications for HFCWO

Covered when ALL of the following are met for HFCWO:

Indication: Member has neuromuscular disease, bronchiectasis, or cystic fibrosis

From Coverage Rationale

Initial trial: An initial 2-month rental trial is completed to confirm individual tolerance and efficacy2-month trial

Required before ongoing medical necessity determination

Ongoing authorization: Continued medical necessity for ongoing use is supported by InterQual® clinical coverage criteria for airway or secretion clearance devicesInterQual criteria

Refer to InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG

Not Medically Necessary / Unproven Uses

Not covered / not medically necessary:

Other conditions: HFCWO is unproven and not medically necessary for conditions other than neuromuscular disease, bronchiectasis, and cystic fibrosis due to insufficient evidence of efficacy

Coverage Rationale

Combination CPAP/continuous HFO/nebulization devices: Combination CPAP/continuous high-frequency oscillation/nebulized medication therapy devices are considered unproven and not medically necessary

Instructions for Use

Intrapulmonary percussive ventilation devices for home use are considered unproven and not medically necessary

Instructions for Use

Combination OLE devices — Not medically necessary

Coverage stance for combination OLE devices:

Not medically necessary for OLE devices: Combination continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings.

Policy statement

HFCWO devices — Evidence synthesis

Evidence summary regarding HFCWO devices (clinical outcomes and limitations):

Observational/registry and cohort findings: Registry and cohort studies report reductions in respiratory-related hospitalizations, antibiotic use, and improved self-reported respiratory health after initiation of HFCWO in bronchiectasis and neuromuscular disease populations, but these studies lack randomized concurrent controls and have limitations in design and usage details.

Examples: Barto et al., Lechtzin et al., Fitzgerald et al.

Randomized and small trials: Randomized trials and small RCTs comparing HFCWO with other airway clearance techniques show mixed or comparable short-term effects on sputum, physiologic measures, and quality-of-life measures; many trials are small with short follow-up, limiting conclusions about long-term clinical benefit.

Examples: Nicolini et al., González-Bellido et al., others

Systematic reviews and meta-analyses report low-to-very-low certainty evidence overall, with few high-quality studies and limited ability to pool results; some analyses noted no clear superiority of oscillatory devices over other ACTs and occasional findings favoring mask-delivered PEP for fewer exacerbations in CF.

Examples: Morrison and Milroy; Cochrane reviews

Evidence-based coverage considerations

Coverage considerations based on available evidence and guideline statements:

Oscillatory devices (HFCWO) for cystic fibrosis: Systematic reviews found low to very low quality evidence with no clear superiority of oscillating devices over other ACTs; routine coverage for superiority is not supported.

Systematic review findings

OLE (combination continuous PEP + continuous HFO): Nonrandomized prospective multicenter data showed reduced postoperative pulmonary complications and reduced ventilator time and hospital length of stay in a high-risk surgical cohort, but authors call for well-designed RCTs to confirm efficacy.

Prospective nonrandomized data

Intrapulmonary percussive ventilation (IPV): RCTs and systematic reviews provide weak or inconsistent evidence for IPV; some inpatient trials report modest benefits (e.g., shorter ICU stay), but overall evidence is insufficient to support routine long-term home use.

RCT and systematic review findings

Combination devices that pair CPAP/continuous high-frequency oscillation with nebulized medication are considered unproven and not medically necessary for coverage. The policy states that such combination CPAP/continuous HFCWO/nebulized therapy systems and intrapulmonary percussive ventilation (IPV) devices for home use lack sufficient evidence to support coverage and are classified as not medically necessary.

Devices that combine continuous positive expiratory pressure (continuous PEP), continuous high-frequency oscillation, and nebulized medication for oscillation and lung expansion (so-called OLE devices) are considered unproven and not medically necessary because of insufficient quality of evidence and inconsistent findings across studies.

The NICE guidance recommends that HFCWO should not be offered as an airway clearance technique for people with cystic fibrosis except in exceptional clinical circumstances determined by the specialist cystic fibrosis team. The guidance notes evidence that HFCWO is not as effective as some other ACTs and recommends individualized assessment and regular reassessment of technique and adherence.

FDA clearance or approval is provided for context only; the policy clarifies that FDA approval alone is not a basis for coverage. Coverage determinations are based on clinical evidence and policy criteria rather than regulatory status alone.

The policy affirms that HFCWO is considered proven and medically necessary only for members with neuromuscular disease, bronchiectasis, or cystic fibrosis when the coverage criteria are met; for all other conditions, HFCWO is described as unproven and not medically necessary due to insufficient evidence of efficacy.

Combination oscillation and lung expansion (OLE) devices that integrate continuous PEP, continuous high-frequency oscillation, and nebulized medication are characterized as unproven and not medically necessary. The policy cites insufficient quality evidence and inconsistent results from the literature as the basis for excluding these combination OLE devices from coverage.

Evidence for intrapulmonary percussive ventilation (IPV) and other oscillatory devices does not support routine, long-term home therapy. Systematic reviews and trials report inconsistent physiologic and clinical effects, limited sample sizes, and occasional adverse events; therefore routine long‑term home use is not supported by sufficiently strong evidence to warrant coverage.

Applicable Codes

Applicable HCPCS/Device CodesHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient- owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient- owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each.

Applicable ICD-10 Diagnosis Codes (selected excerpts)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
B91	Sequelae of poliomyelitis.
E84.0	Cystic fibrosis with pulmonary manifestations.
G12.21	Amyotrophic lateral sclerosis.
G71.11	Myotonic muscular dystrophy.
J47.9	Bronchiectasis, uncomplicated.
Z99.11	Dependence on respirator [ventilator] status.

Informational device codemixed

BYI	FDA product code referenced for HFCWO devices

FDA Product Codemixed

BYI	FDA product code referenced for HFCWO devices

Provider Actions, Prior Authorization, and Step Therapy

Prior Authorization

Prior Authorization Note — OLE and Similar Devices

Prior authorization: Combination OLE devices (continuous PEP + continuous high-frequency oscillation + nebulized medication) and intrapulmonary percussive ventilation devices for home use are considered unproven and not medically necessary. Requests for these devices should be routed through prior authorization. Provide documentation that justifies medical necessity and addresses the low quality and inconsistency of evidence supporting these technologies.

Combination OLE devices (continuous PEP + continuous high-frequency oscillation + nebulized therapy) — considered unproven and not medically necessary
Intrapulmonary percussive ventilation devices for home use — considered unproven and not medically necessary

Step Therapy

Rental Trial as a Step for HFCWO Coverage

An initial 2-month rental trial of an HFCWO system is required and functions as a step to confirm individual tolerance and efficacy before continuing coverage for ongoing use. Requests for continuation beyond the 2-month rental must include documentation of the trial, demonstration of proper use, and evidence that the device provided clinical benefit.

Medical Necessity Criteria and Considerations

DME Medical Necessity Criteria for HFCWO

Equipment is medically necessary when all of the following are met:

Condition: Member has neuromuscular disease, bronchiectasis, or cystic fibrosis

Coverage Rationale

Initial rental: A 2-month rental trial demonstrates individual tolerance and efficacy2 months

Required before ongoing medical necessity determination

InterQual: Continued medical necessity is supported by InterQual® clinical coverage criteria for airway or secretion clearance devicesInterQual criteria

Rental Trial and Purchase Rules

Equipment	Purchase vs Rental Rule	Notes / Requirement
High-frequency chest wall oscillation (HFCWO) system (vest and air-pulse generator)
Initial coverage via a 2-month rental trial
An initial 2-month rental trial must confirm individual tolerance and efficacy before ongoing medical necessity can be determined; continued use requires meeting InterQual® clinical coverage criteria.

Equipment	Purchase vs Rental Rule	Notes / Requirement
High-frequency chest wall oscillation (HFCWO) systems (general reference in observational studies)
Not specified in study reports / payer rule not stated in excerpt
Registry and cohort publications describe home use and potential clinical benefits but do not specify payer rental versus purchase rules; refer to payer policy for coverage mechanics.

Item	Purchase vs Rental Rule	Notes / Requirement
HFCWO device (informational/FDA product code BYI)
Unspecified by device labeling — payer may follow existing DME rental/purchase policies
Devices are FDA-cleared (product code BYI) and are designed to promote airway clearance; payer-specific rental vs purchase determinations are per DME policy and not specified in this excerpt.

Documentation Requirements and Prior Authorization Evidence

Documentation Required

Document 2-month trial, clinical response, and adherence

Document the initial 2-month rental trial, the member's clinical response and adherence to therapy, and supply the relevant medical records as outlined in the Medical Records Documentation Used for Reviews section.

Record trial start/end dates, adherence (e.g., usage logs), and clinical outcomes during the trial

Documentation Required

Provide clinical rationale and supporting documentation

Provide a clinical rationale and supporting documentation that demonstrates the need for HFCWO and the expected clinical benefit given the limited high-quality evidence base.

Address observational evidence limitations and explain why HFCWO is expected to benefit this patient

Documentation Required

Not Covered / Excluded Uses

The policy explicitly lists as NOT COVERED the use of HFCWO for indications other than neuromuscular disease, bronchiectasis, and cystic fibrosis. It also excludes combination continuous PEP/continuous HFO/nebulized therapy devices and home intrapulmonary percussive ventilation systems as unproven and not medically necessary.

Combination continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy devices (OLE devices) are NOT COVERED due to inadequate evidence quality and inconsistent study findings.

Routine, long-term home use of intrapulmonary percussive ventilation (IPV) and similar oscillatory devices is NOT COVERED because the systematic reviews and trials do not provide sufficiently strong, consistent evidence to support ongoing home coverage.

Background and Scope

Airway clearance relies on coordinated ciliary action and effective cough; conditions such as cystic fibrosis, neuromuscular disease, and bronchiectasis can impair clearance, increasing risk of infection and lung-function decline. HFCWO uses an external inflatable vest and air-pulse generator to oscillate the chest wall and mobilize secretions, while IPV delivers internal percussive breaths via a mouthpiece. Device selection should be individualized to the clinical scenario, patient ability to use the technique, and available evidence.

Definitions

Bronchiectasis — definition and diagnostic notes

DefinitionBronchiectasis is a chronic respiratory disease characterized by dilation (ectasia) of the airways or bronchi with recurrent, chronic, or refractory infections.

Clinical featuresClinically significant bronchiectasis has at least two of: cough most days of the week, sputum production most days of the week, or a history of exacerbations.

Diagnostic confirmationPresence of bronchiectasis is confirmed and classified radiographically by high-resolution, spiral, or standard computed tomography (CT) scan.

OLE (oscillation and lung expansion) devices — definition and coverage note

DefinitionOLE devices are combination systems that provide continuous positive expiratory pressure (PEP), continuous high-frequency oscillation, and nebulized medication delivery for oscillation and lung expansion therapy.

Coverage stance

Policy Summary

PayerUnitedHealthcare

PolicyHigh-frequency chest wall oscillation (HFCWO) airway clearance devices — Medical necessity and coverage

Policy CodePolicy CS054.W

Change TypeCoverage criteria clarifieddocumentation requirements added

Effective DateMar 1, 2026

Next Review Date

Key ActionDocument an initial 2-month rental trial demonstrating tolerance and efficacy and submit required medical records for prior authorization.

SourceLink

On This Page

Neuromuscular disease considerations: Guidelines (ATS) emphasize assisted cough technologies and MI-E for patients with neuromuscular weakness and note that devices reliant on normal cough (including HFCWO) may be less effective without assisted cough; thresholds cited include PCF < 270 L/min or maximal expiratory pressure < 60 cm H2O.PCF < 270 L/min; MEP < 60 cm H2O

Guideline recommendations

Guideline restriction for cystic fibrosis: NICE recommends not offering HFCWO for cystic fibrosis except in exceptional clinical circumstances determined by a specialist cystic fibrosis team.

NICE guidance

Initial 2-month rental trial required to establish tolerance and efficacy
Continuation requests must document successful trial and ongoing benefit

Denial Risk

Evidence Limitations May Affect Coverage

Evidence quality across systematic reviews and comparative studies is low to very low for many airway clearance technologies, and findings are often inconsistent or equivocal. Coverage determinations may be affected by these limitations; strong supporting documentation is required when evidence is limited or conflicting.

Low-to-very-low quality evidence across many comparisons of ACTs and oscillatory devices
Inconsistent or equivocal findings may trigger additional documentation requests or denial

Documentation Required

Evidence Limitations and Documentation Context

When clinical evidence is limited (for example, observational studies without concurrent comparators or studies with risk of bias), reviewers will weigh the study limitations when considering coverage. Observational claims-based analyses that show reduced hospitalizations or costs may be confounded by selection bias and lack of concurrent comparators; such findings alone are insufficient to establish efficacy.

Observational studies without concurrent comparison groups are limited by potential selection bias
Claims-based reductions in hospitalizations or costs require corroborating clinical data

Documentation Required

Documentation Expectations for OLE Requests

For OLE or combination therapy device requests, include detailed clinical documentation: surgical/procedural risk (if applicable), procedure type, indication, and rationale for combination therapy; duration and results of prior treatments; and justification for why standard ACTs are inadequate or contraindicated.

Document surgical risk and procedure type for perioperative or post-operative OLE use
Provide rationale for combination therapy over standard ACTs and supporting clinical data

Documentation Required

Required Medical Records Documentation and Denial Risk

Medical records submitted for reviews must include updated, specific elements: the exact device being requested and whether the request is for an initial trial or continuation; results of recent relevant imaging and diagnostic testing; comorbidities; and, for continuation beyond the two-month trial, documentation of proper use and benefit. Failure to provide required documentation — including evidence of a completed 2-month rental trial when continuation is requested — may result in denial.

Specific device requested and trial status (initial vs ongoing)
Results of recent relevant imaging and diagnostic testing
Comorbidities and other clinical context
For continuation: documentation of proper device use and demonstrated benefit
Failure to document 2-month trial or meet InterQual criteria may lead to denial

Refer to InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG

HFCWO — contextual medical necessity considerations

When considering HFCWO device coverage, reviewers should weigh observational benefits against study limitations.

Supportive observational evidence: Decreased hospitalizations, antibiotic use, and improved self-reported respiratory outcomes have been reported after HFCWO initiation in registry and cohort studies, but these lack randomized comparators and may reflect selection bias.

Barto et al., Lechtzin et al., Fitzgerald et al.

RCT and short-term trial evidence: Small RCTs and short-term studies show mixed or comparable results between HFCWO and other ACTs for sputum weight, oxygenation, imaging, and select lung function metrics; long-term clinical benefit remains uncertain due to limited sample sizes and follow-up.

Nicolini et al., González-Bellido et al., others

DME medical necessity examples

Device selection should be individualized and supported by clinical indicators or guideline-based thresholds where available:

Neuromuscular weakness indication for assisted cough/MI-E: Patient has clinical history suggesting difficulty clearing secretions AND peak cough flow (PCF) < 270 L/min or maximal expiratory pressure < 60 cm H2O.PCF < 270 L/min; MEP < 60 cm H2O

ATS guideline-based thresholds

Medical necessity criteria (refer to full policy)

Policy updates reference clinical coverage criteria for HFCWO systems; detailed criteria are in the Coverage Rationale (not included in this excerpt).

See full policy: Refer to the Coverage Rationale section of the full policy for the specific medical necessity criteria; this excerpt documents that the criteria language was updated on 03/01/2026.

Policy History/Revision Information

Physician rationale and clinical indication required

Include a physician statement that external chest manipulation is the chosen treatment and document the clinical indication for HFCWO use (for example, inability to clear secretions, postoperative PPC risk, or neuromuscular weakness).

Physician statement selecting external chest manipulation as treatment of choice
Specify clinical indication (e.g., inability to clear secretions, surgical risk, neuromuscular disease)

Billing Rule

Submit required items with prior authorization/medical records

When submitting prior authorization or medical records, include the documentation elements added to the policy: specific device requested and trial status; results of recent relevant imaging and diagnostic testing; comorbidities; and for continuation beyond the two-month trial, demonstration of proper use.

Specific device and whether request is initial trial or continuation
Recent imaging/diagnostic results and comorbidity list
Evidence of proper use for continuation requests

Due to insufficient quality evidence or inconsistent findings, combination continuous PEP + continuous high-frequency oscillation + nebulized therapy devices (OLE) are considered unproven and not medically necessary.

Clinical contextNonrandomized prospective data suggest potential reductions in postoperative pulmonary complications in selected high-risk surgical cohorts, but well-designed RCTs are needed to confirm efficacy.

High-frequency chest wall compression devices — definition

DefinitionHigh-frequency chest wall compression devices are external systems designed to promote airway clearance and improve bronchial drainage by applying high-frequency compression of the chest wall.

IndicationIndicated when external chest manipulation is the physician's chosen treatment to enhance mucus transport.

Regulatory noteFDA product code BYI is associated with these devices (informational).

IPV — intrapulmonary percussive ventilation definition and evidence

DefinitionIntrapulmonary percussive ventilation (IPV) delivers internal percussive breaths (rapid mini-bursts) intended to mobilize secretions and improve gas exchange.

Evidence summaryThere is insufficient quality evidence or consistency of findings to support routine long-term home use of IPV devices.

Clinical trial noteAn RCT in nonventilated critically ill patients showed shorter ICU length of stay and modest improvements in oxygenation with IPV, but study limitations affect generalizability.

OLE — oscillation and lung expansion therapy definition and notes

DefinitionOscillation and lung expansion (OLE) therapy combines continuous high-frequency oscillation with continuous positive expiratory pressure (PEP), often with nebulized medication, to reduce postoperative pulmonary complications and support lung expansion.

Study findingsA multicenter, nonrandomized prospective study reported reduced postoperative pulmonary complications and shorter ventilator and hospital time in a high-risk surgical cohort receiving OLE, but authors call for RCTs.

Coverage implicationCombination OLE devices are considered unproven and not medically necessary due to insufficient quality or consistency of evidence.

High-frequency chest wall compression (HFCWO) device — definition and purpose

Device descriptionA high-frequency chest wall compression (HFCWO/HFCWC) device is an external system (typically a vest plus air-pulse generator) that delivers simultaneous external oscillation to the anterior and/or posterior thoracic region to mobilize secretions and improve bronchial drainage.

PurposeDesigned to promote airway clearance and improve bronchial drainage when external chest manipulation is chosen as the treatment to enhance mucus transport.

Regulatory/referenceFDA product code BYI is referenced for these devices (informational only).